CatalystS-1 Filing
Rezera filed for an IPO with ruvonoflast, an oral NLRP3 inhibitor that cleared Phase 2 in peripheral artery disease and goes into a Phase 3 registrational study in H1 2027. Net loss of $42.2M, going-c
Rezera filed for an IPO with ruvonoflast, an oral NLRP3 inhibitor that cleared Phase 2 in peripheral artery disease and goes into a Phase 3 registrational study in H1 2027. Net loss of $42.2M, going-c
What changed
Rezera filed for an IPO with ruvonoflast, an oral NLRP3 inhibitor that cleared Phase 2 in peripheral artery disease and goes into a Phase 3 registrational study in H1 2027. Net loss of $42.2M, going-c
Why it matters
Rezera filed for an IPO with ruvonoflast, an oral NLRP3 inhibitor that cleared Phase 2 in peripheral artery disease and goes into a Phase 3 registrational study in H1 2027. Net loss of $42.2M, going-c — impact context not separately stored; see What changed.
← Dashboard
Oct 21, 2026 08:52 PM ET